Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics

REFERENCES

• Nangalia J, Grinfeld J, Green AR. Pathogenesis of myeloproliferative disorders. Annu Rev Pathol 2016; 11:101-26; PMID:27193452; http://dx.doi.org/10.1146/annurev-pathol-012615-044454
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, et al. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol 2015; 95(4):270-9; PMID:25951317; http://dx.doi.org/10.1111/ejh.12578
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20):2391-405; PMID:27069254; http://dx.doi.org/10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124(16):2507-13; PMID:25037629; http://dx.doi.org/10.1182/blood-2014-05-579136
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Kern W, Schröder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006; 20(12):2195-7; PMID:16871281; http://dx.doi.org/10.1038/sj.leu.2404325
   PubMed Web of Science ®Google Scholar
• Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL, Issa JP, Hermouet S. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2. Leukemia 2010; 24(5):1069-73; PMID:20182460; http://dx.doi.org/10.1038/leu.2010.23
   PubMed Web of Science ®Google Scholar
• Chaligné R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socié G, Bordessoule D, Le Bousse-Kerdilès MC, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008; 22(8):1557-66; http://dx.doi.org/10.1038/leu.2008.137
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, et al. Characterization of 35 new cases with four different MPL W515 mutations and essential thrombocythemia or primary myelofibrosis. Haematologica 2009; 94(1):141-4; PMID:19029146; http://dx.doi.org/10.3324/haematol.13224
   PubMed Web of Science ®Google Scholar
• Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, Longtine JA, Sabath D, Wang YL. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the association for molecular pathology. J Mol Diagn 2013; 15(6):733-44; PMID:23978506; http://dx.doi.org/10.1016/j.jmoldx.2013.07.002
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood 2016; 127(3):325-32; PMID:26423830; http://dx.doi.org/10.1182/blood-2015-07-661835
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédiec JP, Droin N, Chachoua I, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients. Blood 2016; 127(3):333-42; PMID:26450985; http://dx.doi.org/10.1182/blood-2015-07-661983
   PubMed Web of Science ®Google Scholar
• Angona A, Fernández-Rodríguez C, Alvarez-Larrán A, Camacho L, Longarón R, Torres E, Pairet S, Besses C, Bellosillo B. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J 2016; 6(8):e463; PMID:27564461; http://dx.doi.org/10.1038/bcj.2016.75
   PubMedGoogle Scholar
• Kirschner MM, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S, Ortiz-Brüchle N, Schmitt K, Krüger K, Zerres K, et al. Dissecting genomic aberrations in myeloproliferative neoplasms by multiplex-PCR and next generation sequencing. PLoS One 2015; 10(4):e0123476; PMID:25894969; http://dx.doi.org/10.1371/journal.pone.0123476
   PubMedGoogle Scholar
• Magor GW, Tallack MR, Klose NM, Taylor D, Korbie D, Mollee P, Trau M, Perkins AC. Rapid molecular profiling of myeloproliferative neoplasms using targeted exon resequencing of 86 genes involved in JAK-STAT signalling and epigenetic regulation. J Mol Diagn 2016; 18(5):707-18; PMID:27449473; http://dx.doi.org/10.1016/j.jmoldx.2016.05.006
   PubMed Web of Science ®Google Scholar
• Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, Meggendorfer M. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol 2016; 175(3):419-26; PMID:27447873
   PubMed Web of Science ®Google Scholar
• Hussein K, Percy M, McMullin MF, Schwarz J, Schnittger S, Porret N, Martinez-Aviles L, Bellosillo-Paricio B, Giraudier S, Skoda R, et al. Clinical utility gene card for: hereditary thrombocythemia. Eur J Hum Genet 2014; 22(2):e1-e5; PMID:23736217; http://dx.doi.org/10.1038/ejhg.2013.117
   PubMed Web of Science ®Google Scholar
• Nelson ND, Marcogliese A, Bergstrom K, Scheurer M, Mahoney D, Bertuch AA. Thrombopoietin measurement as a key component in the evaluation of pediatric thrombocytosis. Pediatr Blood Cancer 2016; 63(8):1484-7; PMID:27100794; http://dx.doi.org/10.1002/pbc.26032
   PubMed Web of Science ®Google Scholar
• Randi ML, Geranio G, Bertozzi I, Micalizzi C, Ramenghi U, Tucci F, Notarangelo LD, Ladogana S, Menna G, Giordano P, et al. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Br J Haematol 2015; 169(4):584-9; PMID:25716342; http://dx.doi.org/10.1111/bjh.13329
   PubMed Web of Science ®Google Scholar
• Swierczek S, Lima LT, Tashi T, Gregg XT, Prchal JT. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 2015; 29(12):2432-4; PMID:26369983
   PubMed Web of Science ®Google Scholar
• Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm 2015; 2015:145293; PMID:26538820
   PubMed Web of Science ®Google Scholar